000			02137na a2200265 4500
003			PC6590
005			20210706062654.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
010			_a
024			_a
040			_cH12O
041			_aeng
100			_91250 _aDelgado Jiménez, Juan Francisco _eCardiología
245	0	0	_aProliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions _h[artículo]
260			_bClinical Transplantation, _c2011.
300			_a25(5):E475-E86.
337			_a
500			_aFormato Vancouver: Epailly E, Albanell J, Andreassen A, Bara C, Campistol JM, Delgado JF, et al. Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions. Clin Transplant. 2011;25(5):E475-86.
501			_aPMID: 21592231
504			_aContiene 119 referencias.
520			_aAlthough malignancy is a major threat to long-term survival of heart transplant (HT) recipients, clear strategies to manage immunosuppression in these patients are lacking. Several lines of evidences support the hypothesis of an anticancer effect of proliferation signal inhibitors (PSIs: mammalian target of rapamycin [mTOR] inhibitors) in HT recipients. This property may arise from PSI's ability to replace immunosuppressive therapies that promote cancer progression, such as calcineurin inhibitors or azathioprine, and/or through their direct biological actions in preventing tumor development and progression. Given the lack of randomized studies specifically exploring these issues in the transplant setting, a collaborative group reviewed current literature and personal clinical experience to reach a consensus aimed to provide practical guidance for the clinical conduct in HT recipients with malignancy, or at high risk of malignancy, with a special focus on advice relevant to potential role of PSIs.
710			_9119 _aServicio de Cardiología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc6590.pdf _ySolicitar documento
942			_2ddc _cART _n0
999			_c6590 _d6590